… compare all currently available anticoagulant treatments as well as aspirin for stroke prevention
in patients with NVAF in France… Given the absence of a cost-effectiveness threshold, the …

… frontier while dabigatran and rivaroxaban were dominated. … apixaban to be the most optimal
OAC, followed by dabigatran… for patients treated with second-line aspirin based on patients …

… or coumarin therapy were assumed to switch to aspirin after an … first study comparing the
cost effectiveness of the new oral … ], France [54], Italy [55], Norway [56], and the UK [57]. Overall, …

… atrial fibrillation by using novel oral anticoagulants apixaban … -term cost-effectiveness of stroke
prevention in patients with … States comparing NOACs with the standard treatment, warfarin. …

… novel oral anticoagulant apixaban represents a cost-effective option versus aspirin and
warfarin for the prevention of stroke … the comparative cost effectiveness of apixaban from …

… effectiveness (VKA rates and comparative effectiveness). A previous … 18 cost-effectiveness
models comparing rivaroxaban and other NOACs with VKAs for stroke prevention in patients …

… of apixaban versus warfarin and aspirin or other new oral … to directly compare the ICERs of
cost-effectiveness analysis included. … Cost effectiveness of new oral anticoagulants for stroke …

… safety than rivaroxaban, similar safety to dabigatran, and similar effectiveness than rivaroxaban
in patients initiating oral anticoagulant (… In France, cost-effectiveness studies have shown …

… were calculated using relative rates of dabigatran, rivaroxaban, apixaban, and edoxaban (…
into account costs of medicines in Germany, Austria and France. If we assume that the cost of …

… of oral anticoagulation treatment for the prevention of stroke in … (dabigatran etexilate) and
factor Xa inhibitors (rivaroxaban, … comparative treatment effect for rivaroxaban and apixaban vs …